Journal article
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.
Abstract
PURPOSE: MET and AXL mediate resistance to EGFR TKI in NSCLC. Foretinib, a MET/RON/AXL/TIE-2/VEGFR kinase inhibitor may overcome EGFR kinase resistance. This dose escalation study combined foretinib and erlotinib in advanced pretreated NSCLC patients. EXPERIMENTAL DESIGN: The primary endpoint was to define the RP2D of foretinib plus erlotinib as continuous oral daily dosing. Secondary objectives included safety, pharmacokinetics, response and …
Authors
Leighl NB; Tsao M-S; Liu G; Tu D; Ho C; Shepherd FA; Murray N; Goffin JR; Nicholas G; Sakashita S
Journal
Oncotarget, Vol. 8, No. 41, pp. 69651–69662
Publication Date
September 19, 2017
DOI
10.18632/oncotarget.18753